Cargando…
A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice
Treatment of multiple myeloma with bortezomib can result in severe adverse effects, necessitating the development of targeted inhibitors of the proteasome. We show that stable expression of a dominant-negative F-box deleted (ΔF) mutant of the E3 ubiquitin ligase, SCF(β-TrCP/FWD1), in murine 5TGM1 my...
Autores principales: | Sharma, Ramaswamy, Williams, Paul J., Gupta, Anjana, McCluskey, Brandon, Bhaskaran, Shylesh, Muñoz, Steve, Oyajobi, Babatunde O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673288/ https://www.ncbi.nlm.nih.gov/pubmed/26009993 |
Ejemplares similares
-
Datasets from an interaction proteomics screen for substrates of the SCF(βTrCP) ubiquitin ligase
por: Magliozzi, Roberto, et al.
Publicado: (2015) -
Regulation of Interleukin-10 Receptor Ubiquitination and Stability by Beta-TrCP-Containing Ubiquitin E3 Ligase
por: Jiang, Hui, et al.
Publicado: (2011) -
Small molecule and peptide inhibitors of βTrCP and the βTrCP–NRF2 protein–protein interaction
por: Jaffry, Uzma, et al.
Publicado: (2023) -
GSK3-β Stimulates Claspin Degradation via β-TrCP Ubiquitin Ligase and Alters Cancer Cell Survival
por: Cabrera, Elisa, et al.
Publicado: (2019) -
SCFβ‐TrCP ubiquitinates CHK1 in an AMPK‐dependent manner in response to glucose deprivation
por: Ma, Ying, et al.
Publicado: (2018)